Streetbeat News

BHVN

Biohaven Ltd.

https://www.biohaven.com/

Industry

Biotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Open

28.76

Mkt cap

Volume

654K

High

29.65

P/E Ratio

-3.14

52-wk high

60.46

Low

28.52

Div yield

N/A

52-wk low

26.80

Baird analyst Brian Skorney maintains an Outperform rating on Biohaven (NYSE:BHVN) and raises the price target from $58 to $60.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:20 pm

U.S. stocks showed mixed performance with the Nasdaq Composite gaining 0.3%. Energy shares rose by 1.4%, while health care shares fell by 0.2%. The S&P Global manufacturing PMI fell to 47 in September. Kaival Brands Innovations Group surged 169% after a merger announcement, while Elevai Labs dropped 60% following a public offering pricing.

Portfolio Pulse from Avi Kapoor

September 23, 2024 | 4:18 pm

Biohaven Ltd. (NASDAQ:BHVN) announced promising results from a study on their drug candidate, troriluzole, for treating Spinocerebellar Ataxia (SCA), a rare neurodegenerative disease. The study showed significant improvements and a slower disease progression rate. Biohaven plans to submit a New Drug Application to the FDA in late 2024, with potential commercialization in 2025.

Portfolio Pulse from Vandana Singh

September 23, 2024 | 3:22 pm

Biohaven Ltd. shares surged 18.4% after positive study results for Troriluzole. Other stocks like BitFuFu, TeraWulf, and Tesla also saw gains, with Tesla's rise linked to a reiterated Neutral rating by Cantor Fitzgerald.

Portfolio Pulse from Avi Kapoor

September 23, 2024 | 1:53 pm

Black Diamond Therapeutics, Ventyx Biosciences, and Biohaven saw significant stock movements. Black Diamond's shares rose 54% due to positive Phase 2 data for BDTX-1535. Ventyx Biosciences announced a $27M investment from Sanofi, boosting shares by 42%. Biohaven's shares increased 26% after successful study results for Troriluzole.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:10 pm

Biohaven shares rose after the company announced that its study of Troriluzole for treating spinocerebellar ataxia met the primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:43 am

Biohaven Ltd. (NYSE:BHVN) announced positive 3-year results for troriluzole in treating Spinocerebellar Ataxia (SCA), showing significant slowing of disease progression. The study met its primary endpoint, and Biohaven plans to submit a New Drug Application to the FDA in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:32 am

Biohaven Ltd. (NYSE:BHVN) will announce topline data for its Troriluzole Spinocerebellar Ataxia study on September 23, 2024. The study was designed in collaboration with the FDA. A conference call and webcast will be held to discuss the results.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 7:20 am

Several Wall Street analysts initiated coverage on key stocks. ARM Holdings received a Hold rating, Immunic a Buy with a $17 target, Biohaven a Buy with a $57 target, Yelp an Underperform with a $30 target, and Coya Therapeutics a Buy with an $18 target.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 1:27 pm

Jefferies has initiated coverage on Biohaven (NYSE:BHVN) with a Buy rating and set a price target of $57, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:40 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.